<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The antithrombotic and <z:mp ids='MP_0001914'>bleeding</z:mp> time (BT) prolonging effects of TAK-029, a novel GPIIb/IIIa <z:chebi fb="68" ids="48706">antagonist</z:chebi>, were examined in three <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> models </plain></SENT>
<SENT sid="1" pm="."><plain>In guinea pigs, TAK-029 at 30 micrograms/kg (i.v.) inhibited <z:chebi fb="13" ids="16761">ADP</z:chebi>-induced ex vivo platelet aggregation completely and prolonged BT to 4.5 times the control value 5 min after administration, and it prevented thrombotic occlusion in 2 out of 5 animals in a photochemically-induced basilar <z:mp ids='MP_0005048'>thrombosis</z:mp> model </plain></SENT>
<SENT sid="2" pm="."><plain>TAK-029 at 100 micrograms/kg (i.v.) prolonged BT more than 9 times 5 min after administration, and it prevented <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation for over 60 min </plain></SENT>
<SENT sid="3" pm="."><plain>In dogs, TAK-029 at 30 micrograms/kg (i.v.) inhibited <z:chebi fb="13" ids="16761">ADP</z:chebi>-induced ex vivo platelet aggregation by 87% 5 min after administration, and it prevented thrombotic occlusion in injured and stenosed coronary arteries for 22 min without prolonging the BT </plain></SENT>
<SENT sid="4" pm="."><plain>TAK-029 at 100 micrograms/ kg (i.v.) inhibited platelet aggregation completely and prolonged BT 3.6 times 5 min after administration, and it prevented <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation for over 45 min </plain></SENT>
<SENT sid="5" pm="."><plain>In monkeys, TAK-029 at 10 micrograms/kg (i.v.) inhibited <z:chebi fb="13" ids="16761">ADP</z:chebi>-induced ex vivo platelet aggregation by 84% and prolonged BT 4.6 times 5 min after the administration, and it prevented thrombotic occlusion in injured and stenosed carotid arteries for 24 min </plain></SENT>
<SENT sid="6" pm="."><plain>TAK-029 at 30 micrograms/kg (i.v.) completely inhibited platelet aggregation and <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation for over 60 min, and it prolonged BT more than 7.3 times 60 min after administration </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, TAK-029 exerted potent antithrombotic effects with BT prolongation in three different <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> models </plain></SENT>
<SENT sid="8" pm="."><plain>TAK-029 may be effective for the treatment of various arterial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombotic diseases</z:e> </plain></SENT>
</text></document>